New First-Line Treatment in Metastatic Renal Cell Carcinoma

Pembrolizumab (Keytruda®, Merck Inc.), previously FDA approved for various cancers, including advanced non-small cell lung cancer, classical Hodgkin lymphoma, and advanced gastric cancer, has now been granted FDA approval to be administered in conjunction with axitinib (Inlyta®, Pfizer Inc.) as first-line treatment for patients with locally advanced or metastatic renal cell carcinoma (RCC). As an immunotherapy drug, pembrolizumab fights cancer by working with the patient's immune system. The dru...
Continue reading

FDA Expands Pembrolizumab Approval for NSCLC

Previously, pembrolizumab (Keytruda®, Merck Inc.) was approved as a single agent for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 with a tumor proportion score (TPS)  greater than or equal to 50%. The FDA has now expanded approval for first-line pembrolizumab to include patients with stage III NSCLC who do not qualify for surgical resection or definitive chemoradiation or metastatic NSCLC. For patients to qualify for tre...
Continue reading

Pembrolizumab Approved for Merkel Cell Carcinoma

Previously approved for the treatment of several other cancers, including lung, cervical, gastric, liver, head and neck, bladder, and certain types of lymphoma, pembrolizumab (Keytruda®, Merck & Co., Inc.) is now approved for both adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC), a rare skin cancer affecting about 2,000 patients per year. Merkel cell carcinoma is aggressive and challenging to treat, and patients with advanced disease have...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.